Brief: Synaptogenix Responds To FDA Approval Of Aducanumab
07/06/2021 17:10
June 7 (Reuters) - Synaptogenix Inc SNPX.O :
* SYNAPTOGENIX RESPONDS TO FDA APPROVAL OF ADUCANUMAB
Source text for Eikon: ID:nPn3msNXWa
Further company coverage: SNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TAO Synergies
See all newsBrief: Tao Synergies Announces Preliminary Inclusion In Russell Microcap Index For 2026
Brief: Tao Synergies Inc - Increases Tao Holdings to 54,058 Tokens
Brief: Tao Synergies Accelerates Decentralized AI Treasury Strategy With 42,111 Bittensor Tokens
Brief: Synaptogenix Renamed TAO Synergies, New Ticker "TAOX" for AI-Focused Crypto Strategy
Brief: Synaptogenix Announces Initial TAO Acquisition Under Crypto Treasury Strategy